Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 2/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | COMT | P21964 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3347947 | 0.85 | SYK (0.33) | MEN1KMT2APOLBSYKNPC1 | |
| SCHEMBL5796914 | 0.82 | ALDH1A1 (0.41) | PDCD1CD274MEN1KMT2AMAPK1 | |
| SCHEMBL9328286 | 0.77 | COMT (0.40) | MEN1KMT2APOLBSYKNPC1 | |
| SCHEMBL2565144 | 0.76 | TDP1 (0.35) | MEN1KMT2APOLBSYKNPC1 | |
| SCHEMBL6881481 | 0.75 | HPGD (0.36) | MEN1KMT2APOLBSYKNPC1 | |
| SCHEMBL7705609 | 0.75 | MEN1 (0.33) | MEN1KMT2APOLBSYKNPC1 | |
| SCHEMBL9151380 | 0.74 | ACHE (0.35) | PDCD1CD274MEN1KMT2APOLB | |
| SCHEMBL18705898 | 0.74 | — | — | |
| SCHEMBL7818368 | 0.73 | RAB9A (0.38) | MEN1KMT2APOLBSYKNPC1 | |
| SCHEMBL7805516 | 0.73 | PTGS2 (0.36) | MEN1KMT2APOLBSYKNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1503993-A4 | COMPOUNDS, METHODS AND COMPOSITIONS | CYTOKINETICS INC (US) | 2006-05-03 | — | — | EP | claimed |
| EP-1503993-A2 | COMPOUNDS, METHODS AND COMPOSITIONS | Cytokinetics, Inc. (US) | 2005-02-09 | — | — | EP | claimed |
| WO-2003094839-A2 | PYRIMIDINONE COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2003-11-20 | — | — | WO | claimed |
| EP-1539727-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING CELLULAR PROLIFERATIVE DISEASES | CYTOKINETICS INC (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1539727-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2007-04-04 | — | — | EP | disclosed |
| US-7166595-B2 | Compounds, methods and compositions | CYTOKINETICS, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1556357-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-09-13 | — | — | EP | disclosed |
| US-7041676-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1503993-A4 | COMPOUNDS, METHODS AND COMPOSITIONS | CYTOKINETICS INC (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20060019988-A1 | Compounds for treating cell prolifieration disease with of kinesin activity , anticancer activity | CYTOKINETICS, INC. | 2006-01-26 | — | — | US | disclosed |
| US-20060004073-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2006-01-05 | — | — | US | disclosed |
| EP-1556357-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| EP-1539727-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| EP-1503993-A2 | COMPOUNDS, METHODS AND COMPOSITIONS | Cytokinetics, Inc. (US) | 2005-02-09 | — | — | EP | disclosed |
| US-20040116400-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040082567-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040077662-A1 | Compounds, methods and compositions | CYTOKINETICS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004006865-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2003106426-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003094839-A2 | PYRIMIDINONE COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077662-A1 | Compounds, methods and compositions | ALPP, PCNA, MKI67 | PDCD1 4356/4885CD274 4759/4885MEN1 1613/4885 |
| US-20060019988-A1 | Compounds for treating cell prolifieration disease with of kinesin activity , anticancer activity | KIF5B, KIF2C, KIF18A | PDCD1 1031/4885CD274 3251/4885MEN1 2174/4885 |
| US-20060004073-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | PDCD1 4276/4885CD274 4695/4885MEN1 1507/4885 |
| US-20040082567-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | PDCD1 4276/4885CD274 4695/4885MEN1 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.